Aging
Navigate
Research Paper|Volume 12, Issue 24|pp 26199—26220

Ring finger protein 2 promotes colorectal cancer progression by suppressing early growth response 1

Feilong Wei1, Haoren Jing2, Ming Wei3, Lei Liu4, Jieheng Wu5, Meng Wang5, Donghui Han6, Fa Yang6, Bo Yang6, Dian Jiao7, Guoxu Zheng5, Lingling Zhang5, Wenjin Xi5, Zhangyan Guo5, An-Gang Yang5, Weijun Qin6, Yi Zhou2, Weihong Wen8
  • 1Department of Orthopedics, Tangdu Hospital, Fourth Military Medical University, Xi’an 710038, China
  • 2Department of Anorectal Surgery, Tianjin Union Medical Center, Nankai University Affiliated Hospital, Tianjin 300013, China
  • 3Urology Department of No. 989 Hospital, Joint Logistics Support Force of PLA, Luoyang 471000, China
  • 4Department of Gastroenterology, Tangdu Hospital, Fourth Military Medical University, Xi’an 710038, China
  • 5State Key Laboratory of Cancer Biology, Department of Immunology, Fourth Military Medical University, Xi’an 710032, China
  • 6Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi’an 710032, China
  • 7Department of Urology, Tangdu Hospital, Fourth Military Medical University, Xi’an 710038, China
  • 8Institute of Medical Research, Northwestern Polytechnical University, Xi'an 710072, China
* Equal contribution
Received: November 25, 2019Accepted: November 11, 2020Published: December 19, 2020

Copyright: © 2020 Wei et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Ring finger protein 2 (RNF2) is an important component of polycomb repressive complex 1. RNF2 is upregulated in many kinds of tumors, and elevated RNF2 expression is associated with a poor prognosis in certain cancers. To assess the function of RNF2 in colorectal cancer, we examined RNF2 protein levels in 313 paired colorectal cancer tissues and adjacent normal tissues. We then analyzed the association of RNF2 expression with the patients’ clinicopathologic features and prognoses. RNF2 expression was upregulated in colorectal cancer tissues and was associated with the tumor differentiation status, tumor stage and prognosis. In colorectal cancer cell lines, downregulation of RNF2 inhibited cell proliferation and induced apoptosis. Gene microarray analysis revealed that early growth response 1 (EGR1) was upregulated in RNF2-knockdown cells. Knocking down EGR1 partially reversed the inhibition of cell proliferation and the induction of apoptosis in RNF2-knockdown cells. RNF2 was enriched at the EGR1 promoter, where it mono-ubiquitinated histone H2A, thereby inhibiting EGR1 expression. These results indicate that RNF2 is oncogenic in colorectal cancer and may promote disease progression by inhibiting EGR1 expression. RNF2 is thus a potential prognostic marker and therapeutic target in colorectal cancer.